Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
UniQure
2703
UniQure
Health Care
Medical
Technology
Biotechnology
uniQure is a world leader in the development of human gene based therapies for hemophilia B, acute intermittent porphyria, Parkinson’s disease and SanfilippoB.
Suggest edits
Founded
2012
Raised
$78M
Follow us
Also headquartered in Amsterdam
Philips
TNW
ABN AMRO
TomTom
Fairphone
PwC
iCulture
Emerce
Startupbootcamp
Adyen
Companies in the same industry
Comfort Line
Deepcare
Morphogen-IX
BillionToOne
Nuritas
Prospective Research
Hua Medicine
Beijing Gene+ Technology
TopGene
Singleron Biotechnologies
Alexa global traffic share
Twitter followers
Overview
Funding
2
Add info
Latest funding
$20,000,000
Debt financing - 2014
Hercules Technology Growth Capital
$58,000,000
Private equity - 2013
Coller Capital
Team Size
50+
Employees
I work here
Location
Amsterdam
,
The Netherlands
Headquarters
Explore Amsterdam
Xconomy
For Key Study, UniQure Allowed to Swap Hemophilia Gene Therapies
Health
Science
Xconomy
UniQure to Yank Pioneering Gene Therapy From Market in Europe
Health
Science
Xconomy
Struggling UniQure Cuts Gene Therapies, Jobs, in Big Restructuring
Health
Strategy
The Motley Fool
,
Xconomy
Here's Why uniQure N.V.'s Stock Spiked Today --
